4D Molecular Therapeutics (FDMT) Payables (2019 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Payables of $14.7 million for Q1 2026, up 253.94% year-over-year from $4.2 million in Q1 2025, and up 31.66% quarter-over-quarter from $11.2 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Payables (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Payables for 8 consecutive years, with $14.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables rose 253.94% year-over-year to $14.7 million; the TTM figure through Mar 2026 stood at $14.7 million (up 253.94% YoY), while the FY2025 annual figure was $11.2 million, up 154.42% from the prior year.
- Payables climbed to $14.7 million in Q1 2026 per FDMT's latest filing, from $11.2 million in the prior quarter.
- Across five years, Payables topped out at $14.7 million in Q1 2026 and bottomed at $1.5 million in Q3 2022.
- Historically, Payables has averaged $5.0 million across 5 years, with a median of $3.5 million in 2023.
- Annual changes were most pronounced in 2022 — Payables tumbled 60.14% — and 2026, when it soared 253.94%.
- 4D Molecular Therapeutics' Payables stood at $3.3 million in 2022, then rose by 5.81% to $3.5 million in 2023, then advanced by 24.78% to $4.4 million in 2024, then surged by 154.42% to $11.2 million in 2025, then soared by 31.66% to $14.7 million in 2026.
- Business Quant data shows FDMT's Payables at $14.7 million in Q1 2026, $11.2 million in Q4 2025, and $6.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 12.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.52 Mn |
| Mar 31, 2026 | 14.69 Mn |
| Dec 31, 2025 | 11.16 Mn |
| Sep 30, 2025 | 6.86 Mn |
| Jun 30, 2025 | 8.70 Mn |
| Mar 31, 2025 | 4.15 Mn |
| Dec 31, 2024 | 4.39 Mn |
| Sep 30, 2024 | 2.92 Mn |
| Jun 30, 2024 | 3.43 Mn |
| Mar 31, 2024 | 4.22 Mn |
| Dec 31, 2023 | 3.52 Mn |
| Sep 30, 2023 | 4.71 Mn |
| Jun 30, 2023 | 3.49 Mn |
| Mar 31, 2023 | 2.41 Mn |
| Dec 31, 2022 | 3.32 Mn |
| Sep 30, 2022 | 1.48 Mn |
| Jun 30, 2022 | 3.32 Mn |
| Mar 31, 2022 | 2.68 Mn |
| Dec 31, 2021 | 4.76 Mn |
| Sep 30, 2021 | 3.71 Mn |